ATE133449T1 - Infektiöses system zur arzneimittelabgabe - Google Patents

Infektiöses system zur arzneimittelabgabe

Info

Publication number
ATE133449T1
ATE133449T1 AT87303651T AT87303651T ATE133449T1 AT E133449 T1 ATE133449 T1 AT E133449T1 AT 87303651 T AT87303651 T AT 87303651T AT 87303651 T AT87303651 T AT 87303651T AT E133449 T1 ATE133449 T1 AT E133449T1
Authority
AT
Austria
Prior art keywords
drug delivery
delivery system
infectious drug
infectious
retrovirus
Prior art date
Application number
AT87303651T
Other languages
English (en)
Inventor
Francis P Mccormick
Michael Kriegler
Original Assignee
Cetus Oncology Corp
Cancer Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp, Cancer Res Inst filed Critical Cetus Oncology Corp
Application granted granted Critical
Publication of ATE133449T1 publication Critical patent/ATE133449T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT87303651T 1986-04-24 1987-04-24 Infektiöses system zur arzneimittelabgabe ATE133449T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85586586A 1986-04-24 1986-04-24

Publications (1)

Publication Number Publication Date
ATE133449T1 true ATE133449T1 (de) 1996-02-15

Family

ID=25322287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87303651T ATE133449T1 (de) 1986-04-24 1987-04-24 Infektiöses system zur arzneimittelabgabe

Country Status (9)

Country Link
US (2) US5652130A (de)
EP (1) EP0243204B1 (de)
JP (2) JP2773833B2 (de)
AT (1) ATE133449T1 (de)
CA (1) CA1310924C (de)
DE (1) DE3751682T2 (de)
ES (1) ES2083353T3 (de)
GR (1) GR3019460T3 (de)
HK (1) HK38497A (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3990262T1 (de) * 1988-03-21 1991-04-04 Viagene Inc Rekombinante retroviren
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
WO1989009271A1 (en) * 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
DE69032841T2 (de) * 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
WO1990007936A1 (en) * 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
JPH04504361A (ja) * 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
WO1991006658A2 (en) * 1989-10-24 1991-05-16 Cetus Corporation Infective protein delivery system
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
ATE142266T1 (de) * 1989-12-21 1996-09-15 Whitehead Biomedical Inst Verfahren zum transport von molekülen in eukaryotenzellen
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
ATE188740T1 (de) * 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
FI954602L (fi) 1993-11-18 1996-03-18 Viagene Inc Koostumukset ja menetelmät käyttää ehdollisesti letaaleja geenejä
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
EP1683858A3 (de) * 1995-02-21 2006-08-02 Cantab Pharmaceuticals Research Limited Virale Zubereitungen, Vektoren, Immunogene und Impfstoffe
DK0835137T3 (da) * 1995-06-27 2006-03-06 Bavarian Nordic As Indkapslede celler, som danner viruspartikler
AU7567298A (en) * 1997-05-09 1998-11-27 Fred Hutchinson Cancer Research Center (mus dunni) endogenous retroviral packaging cell lines
AU7486898A (en) 1997-05-13 1998-12-08 Stuart D Edwards Global medical treatment method and apparatus
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
ES2151403B1 (es) * 1998-07-13 2001-07-01 Hernandez Bronchud Miguel Linea celular transformada de rata productora de tnf-alfa humano recombinante.
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US6399743B1 (en) 1999-05-14 2002-06-04 Dept. Of Veterans Affairs Isolation and characterization of a rat epidermal growth factor related protein
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
KR100630880B1 (ko) * 1999-12-31 2006-10-02 엘지.필립스 엘시디 주식회사 엑스레이 영상 감지소자 및 그 제조방법
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
MXPA02012747A (es) 2000-06-28 2003-09-25 Amgen Inc Moleculas del receptor de linfopoietina estromica timica y sus usos.
JP2005520781A (ja) * 2001-07-09 2005-07-14 アンチキャンサー インコーポレーテッド 蛍光タンパク質をマーカーとして用いた感染の画像化
WO2003072738A2 (en) * 2002-02-22 2003-09-04 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
JP4852539B2 (ja) 2004-06-22 2012-01-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
WO2006086607A2 (en) * 2005-02-10 2006-08-17 Emory University Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation
US8282918B2 (en) * 2007-07-30 2012-10-09 University Of Iowa Research Foundation Polynucleotides encoding RPA4/RPA32 hybrid polypeptides
EA024751B8 (ru) 2008-06-04 2020-01-31 Амген Инк. Мутанты fgf21 и их применение
EP2358749B1 (de) 2008-10-10 2018-07-18 Amgen, Inc Fgf21-mutanten und ihre verwendungen
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SMT202400036T1 (it) 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
AU2011255203B2 (en) 2010-05-21 2016-01-21 Peptimed, Inc. Reagents and methods for treating cancer
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS605692Y2 (ja) * 1977-06-02 1985-02-22 日本電気株式会社 宅内機器構造
JPS61922Y2 (de) * 1979-12-17 1986-01-13
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
US4663281A (en) * 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
AU4404785A (en) * 1984-05-25 1985-12-31 Dana-Farber Cancer Institute, Inc. Ltr vectors, methods of preparation and use
WO1985005618A1 (fr) * 1984-06-06 1985-12-19 Takeda Chemical Industries, Ltd. Procede de preparation de derives de l'interferon
WO1986000922A1 (en) * 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2571737B1 (fr) * 1984-10-15 1987-02-20 Agronomique Inst Nat Rech Vecteurs de clonage ou d'expression comportant le genome du virus de l'erythroblastose aviaire et cellules transfectees par ces vecteurs
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
US4839284A (en) * 1985-05-16 1989-06-13 New York University Murine host-vector system capable of amplifying and expressing transfected genes
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
AU3069189A (en) * 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same

Also Published As

Publication number Publication date
US5652130A (en) 1997-07-29
ES2083353T3 (es) 1996-04-16
EP0243204B1 (de) 1996-01-24
HK38497A (en) 1997-04-04
CA1310924C (en) 1992-12-01
GR3019460T3 (en) 1996-06-30
JP2843318B2 (ja) 1999-01-06
DE3751682T2 (de) 1996-09-12
JPH10287590A (ja) 1998-10-27
US5635399A (en) 1997-06-03
JP2773833B2 (ja) 1998-07-09
DE3751682D1 (de) 1996-03-07
JPS63157985A (ja) 1988-06-30
EP0243204A2 (de) 1987-10-28
EP0243204A3 (en) 1989-02-22

Similar Documents

Publication Publication Date Title
DE3751682D1 (de) Infektiöses System zur Arzneimittelabgabe
DE3685094D1 (de) Pharmazeutisches praeparat zur kontrollierten freisetzung von wirkstoffen.
DK583789A (da) System til transmucosal indgivelse af den aktive bestanddel af et laegemiddel
DE3586206D1 (de) Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung.
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
ATE218365T1 (de) Stabilisierte mischung auf fibrinogenbasis
DE68915291D1 (de) Verschlusskörpr zur verabreichung einer physiologisch aktiven substanz.
DE3770280D1 (de) Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha.
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
FI892454A0 (fi) Nya bensimidazolderivat, foerfarande foer framstaellning av desamma och farmaceutisk komposition innehaollande desamma.
NL194749B (nl) Stabiel calciumhoudend farmaceutisch preparaat.
FI95653C (fi) Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi
DE3882157D1 (de) Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen.
ES2133295T3 (es) Peptidos ciclicos y su uso.
FI884240A0 (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
NL194431B (nl) Farmaceutische preparaten die ranitidine bevatten.
DE68902300D1 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
FI102282B1 (fi) Menetelmä O-glykosyloidun IGF-1:n valmistamiseksi
DK34687D0 (da) Laegemiddel til nasal anvendelse, dets fremstilling og anvendelse
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
ATE80553T1 (de) Behandlung von viraler infektion.
DE3761561D1 (de) N,n-bis-(4-fluorophenyl)carbamoylacetohydroxamsaeure und diese enthaltende pharmazeutische zusammensetzungen.
IT8622051A1 (it) Composizioni farmaceutiche ad attivita' cicatrizzante
LV10497A (lv) Panemiens vakcinas iegusanai kas satur no HIV-1 virusa apvalka gena atvasinatus polipeptidus
ATE64535T1 (de) Xylometazolinhaltige pharmazeutische praeparate.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee